INTRODUCTION
The appearance in 1981 of a cluster of cases of Kaposi's sarcoma (KS) among homosexual men in New York and other coastal cities in the US was one of the first epidemiological signs of the disease that we now call AIDS. As the epidemic unfolded, it became apparent that patients with HIV infection also had a substantially increased risk for certain types of lymphoma (Box 1). [1] [2] [3] [4] Three tumors are now considered to be AIDS-defining in the setting of HIV infection: KS, certain aggressive B-cell non-Hodgkin's lymphomas and invasive cervical cancer. 4 In addition, individuals with HIV infection are at somewhat increased risk for several other neoplasms, including anal carcinoma, Hodgkin's lymphoma, primary hepato cellular carcinoma, certain leukemias, lung cancer, testicular seminoma and, in children, leiomyosarcoma. 2,5-7 Interestingly, the incidence of many common cancers, such as colon and breast cancer, has not been found to be increased in people with HIV infection. 7, 8 
PATHOGENESIS OF AIDS-RELATED MALIGNANCIES
Most of the tumors that are strongly associated with HIV infection are caused by oncogenic DNA viruses (Table 1) . 2, 9 This relationship was highlighted by the discovery, in 1994, of a new gammaherpesvirus, now called KS-associated herpesvirus (KSHV) or human herpesvirus 8. 9 This virus was shown to be the causative agent of three tumors that arise in AIDS patients: KS, primary effusion lymphoma, and multicentric Castleman's disease. 2, 10 Indeed, the only AIDSassociated tumors that are not known to be strongly associated with oncogenic viruses are certain systemic B-cell lymphomas (Table 1) .
Several factors contribute to the increased incidence of certain types of tumor in patients with HIV infection. Most importantly, HIV-associated immunosuppression compromises the ability to mount an immune response against proteins encoded by the tumor viruses and potentially against cellular tumor antigens. There is evidence that immune dys regulation, and in particular increased levels of pro inflammatory cytokines such as interleukin (IL)-6, might also contribute to the development of certain tumors, including B-cell lymphomas and KS. 2, 3, 11, 12 Another mechanism by which HIV might contribute to KS is through the effects of the HIV Tat PROTEIN. This protein has been reported to enhance the response of KS SPINDLE CELLS to angiogenic factors, 13 and, more recently, to enhance the infection of endothelial cells by KSHV. 14 Not surprisingly, as discussed below, effective therapy against HIV can reduce the incidence of some of these tumors and, in the case of KS, even has antitumor activity.
KS is a multicentric angioproliferative tumor that arises simultaneously in multiple non metastatic sites. 11 KS lesions appear most often on the skin, where they can be macular, nodular, or coalesce to form large plaques. Other frequent sites of involvement are the oral cavity, the gastrointestinal tract, and the lung. KS lesions involve a hyperproliferation of spindle cells, most of which are latently infected with KSHV. It has been suggested that there might be true malignant transformation in advanced cases of KS. In support of this idea, one study provided evidence that nodular KS involves a monoclonal cell population, 15 although other studies have indicated that the lesions are generally polyclonal. KS spindle cells form poorly organized vascular structures, and pooled blood and blood-breakdown products give the lesions their characteristic purplish color. Factors that 10 In both of these diseases, VIRAL LATENT GENES are expressed in the tumor cells and seem to have a direct role in tumor pathogenesis. In AIDSassociated Burkitt's or centroblastic diffuse large B-cell lymphomas, 30-50% of cases are associated with EBV infection, and the role of the virus in tumorigenesis is unclear. It is possible that chronic B-cell stimulation, induced in part by EBV, is an important contributory factor to the increased incidence of these tumors in AIDS, and the polyclonal or oligoclonal nature of some HIV-associated lymphoproliferations implies a multistage process of AIDS lymphomagenesis. It remains possible, however, that other factors, including an as yet undiscovered oncogenic virus, might be involved.
EFFECTS OF HAART ON THE INCIDENCE OF AIDS-RELATED MALIGNANCIES
Some therapeutic benefit and reduced mortality was attained with NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) in patients with HIV infection. 23 The subsequent combination of NRTI with protease inhibitors or non-NRTI achieved almost complete suppression of HIV replication in many patients, along with a marked decrease in opportunistic infections and a substantial improvement in survival. With such highly active antiretroviral therapy (HAART), the development of resistance is substantially delayed or prevented, and patients achieve considerable reconstitution of their CD4 + cell counts, although qualitative immune defects can persist. 23 Since 1996, when HAART became the standard treatment for HIV in developed countries, there has been a marked decrease in opportunistic complications and an overall improvement in survival in HIV patients. The introduction of HAART also resulted in a decrease in the incidence of certain AIDS-related tumors, especially those associated with low CD4 + counts. Studies from the US and Europe described a 50-75% decrease in the incidence of KS and an even greater decrease in the incidence of PCNSL, a tumor that develops most often in patients with less than 50 CD4 + cells/mm 3, 24, 25 Initially, the effects of HAART on the development of systemic ARL were unclear, but more recent studies have generally revealed an overall decrease of about 20-60%. 24, 25 In one large study, the decrease in lymphomas associated with the introduction of HAART could be accounted for by a decrease in the proportion of patients with low CD4 + counts. 25 In contrast to the changes in KS and ARL, the widespread use of HAART failed to reduce the incidence of certain other tumors, such as cervical and anal carcinoma, and there is evidence that lung cancer and Hodgkin's lymphoma might be increasing in the HAART era. 8, 26 The higher incidence of these tumors, which are not associated with profound immuno suppression, might be related to improved survival of HIV-infected patients 26 Hodgkin's lymphoma is associated with subtle immunosuppression, and most cases that develop in HIV-infected patients are EBV-associated. 2 The increasing incidence of this tumor since the development of HAART might be related to HIV-infected patients living longer with partial immune dysfunction.
An important and unresolved question is what trends in HIV-associated malignancies will emerge in the future. We can identify several somewhat conflicting factors that will likely affect the incidence of these tumors. First, it is important to remember that HAART is not curative. Moreover, while the death rate from AIDS has decreased, the number of new cases of HIV infection has remained relatively constant in the developed world; in the US, for example, it is estimated that about 40,000 individuals per year are infected with HIV. 27, 28 Thus, while there is a public perception that AIDS is a disease of the past, the number of indiv iduals living with AIDS in the US has increased by more than 50% since 1996 (Figure 1 ). 27 We do not know what new therapies against HIV will be developed or how problematic HIV resistance will be as patients are treated for decades. It is reasonable to postulate that the cumulative hazard of an HIV-infected individual developing a malignancy might increase as their survival increases, a concept possibly foreshadowed by the increasing incidence of lung cancer and Hodgkin's lymphoma. Thus, while it is possible that the incidence of AIDSrelated malignancies in the developed world will remain low, it is also quite possible that the burden of malignant complications will again increase in concert with the expanding at-risk population living longer with HIV infection. In addition, there could be a shift from AIDSdefining malignan cies that occur at very low CD4 + counts to other tumors that occur with more intact immune systems. There is already evidence that, since the introduction of HAART, an increasing percentage of the deaths in HIVinfected individuals are caused by cancer, especially non-AIDS-defining cancers. 29 Finally, it is worth stressing that in the developing world, and especially in Africa where there is a high prevalence of both HIV-1 and KSHV infection, HIV-related malignancies continue to occur at an extremely high frequency, and, in parts of sub-Saharan Africa, KS now surpasses all other malignancies in frequency. 30, 31 
TREATMENT OF AIDS-RELATED MALIGNANCIES
HIV-infected patients with malignancies confront the treatment team with the problem of how to deal with two complicated life-threatening dis orders. Choosing the optimal therapy for such patients requires an understanding of the goals of therapy, the specific issues related to each condition, and interactions among the therapies under consideration. In many cases, non-AIDS-defining cancers can be treated according to the standards of care in the general population, although physicians should be alert for factors such as underlying immunosuppression, the potential for drug interactions, and the potential for increased toxicity that could impact on therapy. Below is a brief description of the therapy for common AIDS-defining malignancies.
Kaposi's sarcoma
The treatment goal for patients with KS is long-term palliation with minimal toxicity. Complete tumor response, even with long-term disease-free survival, does not imply that the KS has been cured. HIV is an important cofactor for the development of KS, and effective treatment of HIV can induce KS remissions. This 32 and there is now substantial evidence that HAART can induce tumor responses in 20-40% or more of patients with AIDS-related KS, especially those who were previously untreated for HIV. [33] [34] [35] HAART should therefore be considered to be fundamental to the oncological therapy for HIV-associated KS, and should form part of virtually all treatment regimens (Table 2) . There is some laboratory evidence to indicate that HIV protease inhibitors have direct antiangiogenic effects and might promote regression of KS by this mechanism. 36 However, two clinical trials failed to find a difference in the development of KS between patients receiving HAART regimens containing a protease inhibitor and those containing a non-NRTI, 37, 38 and additional studies will be needed to assess whether the potential antiangiogenic effects of protease inhibitors have clinical significance. Finally, physicians should be aware that some patients with AIDS-related KS can experience an initial flare or progression in their KS when started on antiretroviral therapy, which could be a manifestation of immune reconstitution inflammatory syndrome.
Various local therapies can be used in patients with limited mucocutaneous KS, including CRYOTHERAPY, PHOTODYNAMIC THERAPY, radiation therapy and intralesional injections with cytotoxic chemotherapy. Topical 9-cisretinoic acid (Panretin® gel, Bristol-Myers Squibb, Princeton, NJ) has been approved in the US for the treatment of local KS, but can cause local pain and irritation. 39 Systemic KS therapy should be considered if HAART alone is felt to be in sufficient and there is widespread disease that is not amenable to local therapy, or if there is visceral organ involvement, painful lesions, substantial edema or psychosocial withdrawal (Table 2) . [40] [41] [42] [43] [44] [45] Interferon-α is active in KS, especially in patients with relatively intact immune function. 40 Its use, however, is associated with a decreased white blood cell count, flu-like symptoms, and occasionally depression. Many physicians who treat KS feel that the drug of choice for patients requiring systemic therapy is generally one of the liposomal anthracyclines. [41] [42] [43] These are less toxic than the unencapsulated drugs. Even in the pre-HAART era, these drugs yielded response rates in the range of 23-52%, and response rates of up to 70-80% can be seen when they are combined with HAART. 35, [41] [42] [43] Paclitaxel has been reported to have given response rates of 59-71% in the pre-HAART era, [44] [45] but its use is often associated with neutropenia, alopecia and neuropathy.
Although liposomal anthracyclines frequently provide effective therapy in KS, they are palliative, and can be associated with cumulative toxicity. There is therefore an interest in developing therapy that is targeted at the disease patho genesis. Because of the vascularity of the lesions and the involvement of VEGF and other angiogenic factors, antiangiogenic approaches are particularly attractive in KS. 46 Recent small clinical trials have shown that three such compounds-thalidomide, Col-3 and IL-12-all have activity in patients with KS. [47] [48] [49] Other antiangiogenic agents are also being assessed. Moses et al. found that upregulation of the c-kit protooncogene by KSHV is important in the transformation of endothelial cells, 50 
Therapy Comment
HAART Should be used in patients with HIV-associated KS whenever possible, generally in combination with other KS-specific therapy [33] [34] [35] Interferon-α Most active in patients with relatively intact immune function; can cause flu-like symptoms and other side effects 40 Liposomal anthracyclines: Doxorubicin Daunorubicin
Often used as first-line therapy for patients requiring cytotoxic therapy 35, 42, 43 Approved as first-line therapy for advanced KS in the US 41 
Paclitaxel
Responses seen in patients who have failed anthracycline therapy. Greater toxicity than liposomal anthracyclines, including neutropenia and alopecia 44, 45 HAART, highly active antiretroviral therapy; KS, Kaposi's sarcoma. 51 Finally, a recent small study showed that transplant patients with KS can respond to replacement of cyclosporine immunosuppressive therapy with sirolimus (rapamycin), an inhibitor of mTOR (mammalian target of rapamycin) with both immuno suppressive and antineoplastic activity. 52 Additional studies will be needed to assess the utility of this agent in treating patients with AIDS-related KS.
GLOSSARY

ZIDOVUDINE
AIDS-related non-Hodgkin's lymphoma
In patients presenting with systemic ARL, the goal of treatment is to attain a complete response and cure the tumor with acceptable toxicity. This goal needs to be balanced against the treatment of HIV and other HIV-associated complications (Table 3) . [53] [54] [55] [56] [57] [58] [59] Before the HAART era, patients with ARL frequently did not tolerate the toxicity that is associated with cytotoxic chemotherapy, and full-dose intensity did not confer a survival advantage. As a result low-dose regimens such as m-BACOD (moderate dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone) became the standard of care (Table 3) . 53 Studies conducted in the HAART era, however, have provided substantial evidence that most patients with ARL have better outcomes-often comparable to the outcomes of those with non-HIV-related non-Hodgkin's lymphoma-with standarddose therapy. 60 Ratner et al. 54 reported on a study conducted by the US AIDS Malignancies Consortium of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered with HAART (stavudine, lamivudine, and indinavir) in patients with ARL, the primary aims of which were to determine the toxicity of the regimens, the effect on AIDS parameters, and pharmacokinetic interactions. The first 40 patients in this study received modified CHOP therapy given in low doses, and a subsequent cohort of 25 patients received full-dose CHOP. The complete response rates were 30% on the modified CHOP arm and 48% on the full-dose CHOP arm. Overall, the full-dose CHOP was well tolerated and, while it was not randomized, this study can be credited for providing data leading to a re-evaluation and ultimately the end of lowdose chemotherapy as the standard of care in ARL. Moreover, it provided evidence that combination chemotherapy for ARL could be safely coadministered with HAART. Another study by the AIDS Malignancies Consortium examined the use of standard-dose CHOP plus HAART with or without rituximab, a monoclonal antibody directed at CD20. 58 Again, the study showed that full-dose CHOP could be given with HAART. There was a trend towards a higher complete response rate on the rituximab arm (58% versus 47%), but there were substantially more treatment-related infectious deaths in the rituximab arm (14% versus 2%). 58 The majority of these deaths occurred in patients with <50 CD4 + cells/mm 3 at entry. Interestingly, there was no significant difference in the rate of grade 4 neutropenia, febrile neutropenia, or infections between the arms.
Other recent studies have explored the use of infusional regimens of CDE (cyclo phosphamide, doxorubicin and etoposide) or DA-EPOCH (a dose-adjusted regimen of etoposide, prednisone, vincristine, cyclophosphamide and doxo rubicin). 56, 57, 59 One of these studies pooled results from three phase II trials of infusional CDE with rituximab. 59 Most patients also received HAART. The complete response rate of 70% in these pooled results was higher than the previously reported rates of 44% and 47% with infusional CDE alone, 57 but it is unclear whether this was due to the addition of rituximab. Interestingly, patients with detectable HIV viral loads at the end of treatment seemed to show an increased risk of treatment failure, raising the possibility that HAART might have a beneficial effect during antilymphoma therapy. 59 Six of the 74 patients in this trial (8%) died because of infection, and the authors suggested that adding rituximab to cytotoxic therapy in patients with ARL could increase the risk for life-threatening infection. 59 Overall, the role of rituximab in ARL is currently unclear. There appears to be a trend towards higher response rates when rituximab is added to certain cytotoxic chemotherapy regimens for ARL, but at the same time its use might be associated with a higher death rate from infection during treatment, especially in patients with very low CD4 + counts. 58, 59, 61 Additional research will be needed to define the mechanisms by which rituximab contributes to infections in this population and the role of this agent in the treatment of ARL.
A recent phase II study conducted at the National Cancer Institute examined another infusional regimen, DA-EPOCH without rituxi mab. 56 In this study, 74% of patients achieved a complete remission, and at 53 months of median followup, the disease-free and overall survival were 92% and 60%, respectively. This compares favorably with a median survival of about 32 months recently reported with CHOP plus rituximab, 58 and also compares favorably with the overall survival of 65% and disease-free survival of 55% seen at a median of 23 months follow-up on the studies of CDE with rituximab. 59 It is possible, however, that the DA-EPOCH study benefited from patient-selection bias, as it was performed in a single referral hospital. A multi-institutional trial by the AIDS Malignancies Consortium of DA-EPOCH given concurrently or sequentially with rituximab is underway to investigate further this approach.
One argument for combining HAART and cytotoxic chemotherapy for lymphoma is the improved survival of patients with ARL in the HAART era. It is possible, however, that several other factors might contribute to this improved survival, including a greater percentage of goodprognosis tumors in patients on HAART and improved prophylaxis and control of opportunistic infections. In the DA-EPOCH trial, antiretroviral therapy was deferred until all cycles of cytotoxic chemotherapy were completed, because of concern about overlapping toxicities (leading to reduced dose intensity of the lymphoma therapy and skipped doses of antiretroviral therapy with a risk for drug resistance), unpredictable drug interactions, and the possibility that any protective effect of the HAART on CD4 + counts would be lost in the face of cytotoxic chemotherapy. 56 The successful results obtained in this study indicate that HAART can be safely deferred until completion of ARL treatment.
Nevertheless, it is clear that at least some regimens for ARL, such as CHOP and infusional CDE, can be administered with HAART, 54, 59 and there is evidence that some of the theoretical concerns regarding HAART coadministration during ARL therapy do not pose a substantial problem in practice. The concern that dose intensity might be compromised has not been substantiated and, in at least one study, higher dose intensities were achieved when HAART was given. 55 Also, the ability to maintain undetectable HIV viral loads in most studies indicates that antiretroviral adherence is not compromised. Informal comparison of the National Cancer Institute's DA-EPOCH trial with studies in which HAART is given with chemotherapy suggest that CD4 + cell counts might return to the prelymphoma therapy baseline faster when HAART is coadministered. 54, 56, 59 No prospective trials have specifically addressed whether HAART should be administered during antilymphoma therapy, however. In the absence of such guidance, physicians will have to carefully assess the available evidence as it applies to any given patient. When patients are already receiving HAART, some physicians with experience in this area will continue this treatment during lymphoma therapy; they will avoid starting HAART and antineoplastic therapy at the same time, however.
There are few data that address specifically the role of HAART in the treatment of PCNSL, but the available evidence supports its initiation as soon as possible. 62 Before the introduction of HAART, whole-brain radiation therapy was the standard treatment for patients with PCNSL, and, even with this treatment, median survival was generally 2-4 months, owing to recurrent lymphoma or other complications of AIDS. 63 Although radiotherapy remains the standard of care for HIV-associated PCNSL, there is an interest in exploring chemotherapybased approaches with HAART, as a means of reducing the risk of late radiation-induced neurotoxicity.
VIRAL TARGETS IN HIV-ASSOCIATED MALIGNANCIES
There is currently an interest in developing vaccines for human papillomaviruses and other oncogenic viruses that cause AIDS-associated malignancies, and this approach has the potential to reduce greatly the incidence of tumors caused by these viruses. 64 There is also an interest in exploiting viral targets for therapy. Putting this latter approach into practice, however, is proving to be difficult.
In the case of KS, there is evidence that administration of antiherpes drugs can prevent tumor development. The best evidence came from a randomized trial of ganciclovir (Cytovene®, Hoffman-La Roche, Nutley, NJ) in patients with AIDS-associated cytomegalovirus retinitis. 65 There are also several case reports to indicate that occasional patients with KS can respond to antiherpes therapy. However, in a small trial of cidofovir (Vistide®, Gilead Sciences, Inc., Foster City, CA) conducted by our group in the National Cancer Institute, no KS responses were observed. 66 An alternative approach in KS is to activate KSHV lytic replication, which in turn induces cellular apoptosis. The AIDS Malignancies Consortium has initiated a trial of valproic acid 67 to begin to explore this approach (R Ambinder, personal communication).
Similarly, there is an interest in using antiherpes drugs to target lymphomas or other tumors caused by EBV or KSHV. Both of these viruses have kinases that can activate certain drugs-such as zidovudine or ganciclovir-to toxic forms, 68, 69 and several investigators are studying the feasibility of combining viral activation and antiherpes approaches. 70, 71 Case reports have described the activity of such agents in AIDS-related PCNSL or multi centric Castleman's disease, 72, 73 but some animal experiments have indicated that it might be difficult to achieve toxic levels of the antiherpes drugs in tumor cells, 71 and additional research is needed to assess such approaches in various herpesvirus-associated tumors.
CONCLUSION
The development of effective antiretroviral therapy has profoundly changed the epidemiology of AIDS-related complications, including AIDS malignancies. In settings where HAART is available, the incidence of some AIDS malignancies has decreased substantially, although cancer-related mortality has surpassed mortality from infectious complications as the leading cause of death in HIV-infected individuals. 29 Since HAART was introduced, the number of people living with AIDS in the US has increased (Figure 1 ), and these individuals are at risk for developing a wide range of malignancies in the future. Additional research will be needed to develop strategies to reduce the risk of malignant complications in patients with chronic HIV infection and to treat them optimally when their condition develops.
